Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Lilly drops 3 clinical programs, including Prevail gene therapy
Lilly discontinued its GRN gene therapy in frontotemporal dementia "due to a lack of compelling efficacy," a spokesperson told Fierce.
Gabrielle Masson
Feb 4, 2026 12:33pm
Fierce Pharma
FDA’s rare pediatric voucher program revived by funding bill
Feb 4, 2026 3:12pm
Sponsored
Inside Henlius’ global growth strategy
Feb 2, 2026 8:00am
Novartis nixes 6 ph. 1 assets, adds 2 new cancer candidates
Feb 4, 2026 12:09pm
GSK's new CEO looking for $2B-$4B deals 'hiding in plain sight'
Feb 4, 2026 7:25am
Jay Bhattacharya faces Senate grilling on NIH disruptions
Feb 3, 2026 5:20pm
More News
Preclinical stem cell biotech takes SPAC route to Nasdaq
Feb 4, 2026 10:15am
Amgen eyes lupus redemption while cancer candidate struggles
Feb 4, 2026 6:10am
Novo 'wishes Pfizer luck' with Metsera drug, seeks monthly GLP-1
Feb 4, 2026 5:09am
HHS launches $100M prize to develop antiviral therapies
Feb 3, 2026 4:00pm
See more stories